I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Periodontitis is a chronic, multifactorial, infectious disease of the supporting tissues of the teeth. The onset and progression of periodontitis is due to an imbalance of the interaction between bacterial pathogens and host immunity.[@ref1][@ref2]

Host immunity is greatly influenced by both genetic susceptibility and environmental risk factors. Cigarette smoking is considered to be one of the most important environmental risk factors for periodontitis.[@ref3][@ref4] More clinical attachment loss and bone loss have been observed among smokers than among nonsmokers.[@ref5]

Cigarette smoking alters the host response through a plethora of changes that include antibody production, vascular function, activities of neutrophil/monocyte, and finally influencing cytokine and inflammatory mediator release, and thus exhibits a negative impact on the periodontium.[@ref6] Cytokines are low-molecular-weight proteins involved in the initiation and effector stages of immunity and inflammation. The interrelationships of various cytokines and their correlation with periodontitis have been explored through the biochemical analysis of gingival crevicular fluid (GCF). Sampling of GCF provides ease of access, is relatively atraumatic, and can be repeatedly collected. GCF exhibits the lowest bias, the highest reproducibility, and the strongest validity.[@ref7]

Cytokines such as interleukin (IL) IL-1, IL-6, IL-8, and TNF-α are involved in the host response of periodontal disease as mediators of tissue destruction. IL-lβ has pro-inflammatory effects and acts on endothelial cells to promote adhesion and migration of leukocytes into inflamed tissue sites.[@ref8][@ref9] In this context, IL-8 may also play a role in the pathogenesis of inflammation because it promotes neutrophil chemotaxis and activation.[@ref10] Considering the above facts, it seems logical to hypothesize the role of IL-1β and IL-8 in the pathogenesis of periodontal disease.

Smoking alters many aspects of the host\'s immune response, and these alterations may be a major contribution to the pathogenesis of the disease. Smokers have elevated GCF levels of IL-8.[@ref11][@ref12] In other studies, smokers showed decreased levels of certain cytokines in GCF, such as IL-1β and IL-8.[@ref13][@ref14] In a recent study by Fredriksson *et al*., smoking was found to reduce the sensitivity of peripheral neutrophil to stimulation by IL-8 when comparing smoking to nonsmoking patients.[@ref15] This suggests that smoking may interfere with the inflammatory process by affecting the release of pro-inflammatory cytokines. Smoking\'s effect on IL-1β and IL-8 in GCF has not been well characterized. Therefore, this study evaluated the impact of smoking on these two cytokines.

The present study was designed to determine the cytokine levels of IL-1β and IL-8 in GCF from smokers and nonsmokers with periodontitis, with an objective to determine the differences in these levels from disease and healthy sites of smokers and nonsmokers with periodontal disease.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

The present study comprised a cross-sectional study design. A total of thirty male patients aged between 40 and 70 years (15 smokers and 15 nonsmokers) with severe chronic periodontitis were enrolled in this study during January 2014 to April 2014. The patients were randomly selected from the Outpatient Department of Periodontology, Chhattisgarh Dental College and Research Institute, Rajnandagaon, India. Ethical clearance for the study was obtained from the college\'s ethical committee. All the patients had the procedure explained to them, and a written informed consent was obtained from those willing to be part of this study.

 {#sec2-1}

### Sample size {#sec3-1}

The sample size for the present study was based on the preliminary findings related to the variations in IL-β levels expressed in picograms per microliter reported by Tymkiw *et al*.[@ref16] Based on the standard deviation with an error of 0.05 and power at 80%, the calculated sample size was 15 for each representative group.

Selection criteria for the patients {#sec2-2}
-----------------------------------

### Inclusion criteria {#sec3-2}

Presence of good general health and clinical diagnosis of periodontal disease (periodontally diseased patients had a diagnosis of generalized severe chronic periodontitis \[30% of sites with CAL and PD ≥5 mm\]).

### Exclusion criteria {#sec3-3}

Pregnancy or lactation, gingival overgrowth, chronic systemic disease such as diabetes, administration of systemic antibiotics in the last 6 months, and regular use of anti-inflammatory medications in the last 6 months.

### Patient selection {#sec3-4}

Classification of smokers and nonsmokers was adopted from the study by Tymkiw *et al*.[@ref16] Smokers were classified and enrolled if they regularly smoked ≥20 cigarettes per day, and nonsmokers were classified as not having smoked one hundred or more cigarettes in their lifetime.

### Site selection {#sec3-5}

One diseased and one healthy site were selected from each of the smoking and nonsmoking groups. The diseased sites in the smoking patients were labeled as diseased sites in smoker (SD) and healthy sites as healthy sites in smoker (SH). In the nonsmoking group, the diseased sites were labeled as diseased sites in nonsmoker (ND) and the healthy sites were labeled as healthy sites in nonsmoker (NH).

The clinical parameters recorded were bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL), and gingival recession (REC). PD, CAL, and recession measurements were recorded by a calibrated examiner and rounded off to the nearest millimeter with a periodontal probe (UNC-15, Hu-Friedy, Chicago, IL, USA).

Gingival crevicular fluid sample collection {#sec2-3}
-------------------------------------------

The patients were informed about the protocol prior to the collection of GCF. Due to the contamination of the GCF sample with saliva and the difficulties involved in the isolation process, GCF sample collection was predominantly done from the maxillary teeth. The test sites for GCF sample collection in the periodontitis patients comprised of five different nonadjacent sites that exhibited the deepest PD on clinical examination. In the healthy group, to facilitate sufficient volume for the assay, GCF was collected from numerous sites without any inflammation and was pooled up. The samples were collected a day after the clinical parameters were recorded to avoid sample contamination.

Prior to the sampling, each of these selected test sites was air dried gently with a blast of air and isolated with cotton rolls. Supragingival plaque was removed with Gracey curettes (Hu-Friedy), avoiding any contact with the marginal gingiva to pave way for the micropipette in the sample collection. The GCF sample was collected by placing the 1--5 μl calibrated volumetric microcapillary pipettes (Sigma-Aldrich, Chemical Company, St. Louis, Missouri, USA) at the entrance of the gingival sulcus \[[Figure 1](#F1){ref-type="fig"}\]. The GCF sample was collected from all the five sites with a collection time of no more than 5 min from each site, and the collected sample was pooled to calculate the volume. Pooled GCF sample of 3 μl was collected from all these sites. Care was taken to discard the micropipettes contaminated with blood and saliva. GCF collected was immediately transferred to vials and stored at −70°C in a deep freezer till the time of the assay.

![Gingival crevicular fluid sample collection from a diseased periodontal site](NMJ-59-33-g001){#F1}

Interleukin-1β and interleukin-8 assays {#sec2-4}
---------------------------------------

The pooled GCF samples were assayed to measure the IL-1β and IL-8 levels using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) (Quantikine R and D systems, MN, USA) that was specific to human IL-1β and IL-8 assays. The test was run by an expert, blinded to the clinical results as per the manufacturer\'s instructions. The calorimetric reaction in the wells was recognized by an ELISA reader with an optical density value set at 450 nm. The concentrations of IL-1β and IL-8 were reported as picograms per microliter (pg/μl) of the sample.

Statistical analysis {#sec2-5}
--------------------

Statistical analysis was performed using IBM Statistical Program for Social Sciences Version 20.0 (SPSS Inc., Chicago, IL, USA). Intergroup comparisons were done using unpaired *t*-test. Smokers and nonsmokers were compared in relation to healthy and diseased sites. Intragroup comparisons were done using the Wilcoxon matched-pairs signed-rank test between healthy and diseased sites in smokers and nonsmokers. In each case, the level of significance was set at *P* ≤ 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of thirty patients were examined for this study, with 15 participants in each group. The mean age of the smokers group was 50.2 ± 7.8 and that of the nonsmokers group was 60.2 ± 8.7, with the difference in age being not statistically significant.

Clinical parameters {#sec2-6}
-------------------

[Table 1](#T1){ref-type="table"} represents the distribution of the values of the clinical parameters among the study groups. PD was significantly high for the SD group (5.9 \[0.5\], *P* = 0.03) compared to the ND group (5.5 \[0.9\]). PD was high in the SH group (2.8 \[0.4\]) compared to the NH group (2.6 \[0.6\]) and was statistically significant (*P* = 0.06). CAL was also significantly high in the SD group (6.9 \[1.3\], *P* = 0.04) compared to the ND group (6.2 \[1.3\]).

###### 

Distribution of clinical parameters of the study population

  Clinical parameters         NH        SH        ND        SD
  --------------------------- --------- --------- --------- ---------
  PD (mm)                     2.6±0.6   2.8±0.4   5.5±0.9   5.9±0.5
  Recession (mm)              0.3±0.7   0.3±0.4   0.7±0.9   1.0±1.1
  CAL (mm)                    2.9±0.9   3.0±0.3   6.2±1.3   6.9±1.3
  BOP (percentage positive)   0.0±0.0   0.0±0.0   100±0.0   100±0.0

NH -- Healthy sites in nonsmoker; SH -- Healthy sites in smoker; ND -- Diseased sites in nonsmoker; SD -- Diseased sites in smoker; CAL -- Clinical attachment level; BOP -- Bleeding on probing; PD -- Probing depth

Cytokine levels {#sec2-7}
---------------

[Table 2](#T2){ref-type="table"} represents the intragroup comparison of IL-1β and IL-8 levels between healthy and diseased sites in smokers and nonsmokers.

###### 

Intragroup comparisons: Healthy and diseased sites in smokers and nonsmokers

  Cytokine   Mean±SD        *P*            Mean±SD     *P*                       
  ---------- -------------- -------------- ----------- ------------ ------------ ------------
  IL-1β      37.2±17.1      131.5±62.2     \<0.005\*   42.6±4.1     192.2±26.4   \<0.0001\*
  IL-8       1342.4±134.5   2409.1±298.1   NS          743.6±76.7   809.1±61.5   NS

\*Statistically significant. IL-1β and IL-8 levels of NH versus ND and SH versus SD compared using Wilcoxon matched-pairs signed-rank test. NH -- Healthy sites in nonsmoker; SH -- Healthy sites in smoker; ND -- Diseased sites in nonsmoker; SD -- Diseased sites in smoker; SD -- Standard deviation; IL -- Interleukin; NS -- Not significant

There was a statistically significant elevation in the mean levels of IL-1β in ND sites (131.5 (62.2) pg/μl) compared to NH sites (37.2 \[17.1\] pg/μl) (*P* \< 0.005). SD sites showed significantly higher levels of IL-1β (192.2 \[26.4\] pg/μl) compared with SH sites (42.6 \[4.1\] pg/μl) (*P* \< 0.0001). However, there was no significant difference in IL-8 levels between NH and ND sites (1342.4 (134.5) and 2409.1 (298.1) pg/μl, respectively) as well as between SH and SD sites (743.6 (76.7) and 809.1 (61.5) pg/μl, respectively).

Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} represents the intergroup comparison of IL-1β and IL-8 levels between healthy and diseased sites in smokers and nonsmokers.

###### 

Intergroup comparisons: Healthy and diseased sites in smokers and nonsmokers

                              NH             SH           *P*      ND             SD           *P*
  --------------------------- -------------- ------------ -------- -------------- ------------ -----------
  PD (mm)                     2.6±0.6        2.8±0.4      0.06     5.5±0.9        5.9±0.5      0.03\*
  Recession (mm)              0.3±0.7        0.3±0.4      0.06     0.7±0.9        1.0±1.1      0.03\*
  CAL (mm)                    2.9±0.9        3.0±0.3      0.08     6.2±1.3        6.9±1.3      0.04\*
  BOP (percentage positive)   0.0±0.0        0.0±0.0      \-       100±0.0        100±0.0      \-
  IL-1β                       37.2±17.1      42.6±4.1     NS       131.5±62.2     192.2±26.4   NS
  IL-8                        1342.4±134.5   743.6±77.8   \<0.01   2409.1±298.1   809.1±61.5   \<0.001\*

\*Statistically significant. NH -- Healthy sites in nonsmoker; SH -- Healthy sites in smoker; ND -- Diseased sites in nonsmoker; SD -- Diseased sites in smoker; IL -- Interleukin; NS -- Not significant; CAL -- Clinical attachment level; BOP -- Bleeding on probing; PD -- Probing depth

###### 

Comparison of cytokine levels and clinical parameters among all the groups

          Mean±SD        *P*          Mean±SD    *P*                         
  ------- -------------- ------------ ---------- -------------- ------------ -----------
  IL-1β   37.2±17.1      45.6±4.1     NS         131.5±62.2     192.2±26.4   NS
  IL-8    1342.4±134.5   743.6±77.8   \<0.01\*   2409.1±298.1   809.1±61.5   \<0.001\*

\*Statistically significant. NH -- Healthy sites in nonsmoker; SH -- Healthy sites in smoker; ND -- Diseased sites in nonsmoker; SD -- Diseased sites in smoker; IL -- Interleukin; NS -- Not significant; SD -- Standard deviation

There was a statistically significant decrease in the mean levels of IL-8 in SH sites (743.6 (76.7) pg/μl) compared to NH sites (1342.4 (134.5) pg/μl) (*P* \< 0.01), and SD sites (809.1 (61.5) pg/μl) showed significantly lower levels of IL-8 compared to ND sites (2409.1 (298.1) pg/μl) (*P* \< 0.001). However, the comparison of NH and SH sites (37.2 \[17.1\] and 42.6 \[4.1\] pg/μl, respectively) as well as ND and SD sites (131.5 (62.2) and 192.2 \[26.4\] pg/μl, respectively) showed no significant difference in the mean levels of IL-1β.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The objective of the present study was to investigate the influence of smoking on the etiopathogenesis of periodontal diseases through the assessment of potential mediators of inflammation. Literature is replete with abundant evidence[@ref17][@ref18][@ref19] on the positive influence smoking has on periodontal disease, with most of these studies centered on the urban population.[@ref20][@ref21] There is a dearth of articles that have assessed this association in a rural setting. Hence, our study was designed to explore the role of smoking in the pathogenesis of periodontal disease in a rural population through the assessment of levels of mediators of inflammation.

The participants in our study comprised only males, probably because smoking among females is considered a taboo in rural India. Females are, therefore, more addicted to smokeless tobacco and other related products.[@ref22] This point was taken into consideration in our previous study that had included females in correlating the role of gutka chewing on periodontitis and was published elsewhere. Further, GCF volume is influenced by variables such as ovulation, menstruation, and use of hormonal contraceptives; hence, females were excluded to avoid this bias in our study.

Our study evaluated GCF biomarkers using ELISA. A major limitation was that this assay has the capability to evaluate only a limited number of mediators in each sample. A multiplex assay would have made it possible to evaluate a wide range of cytokines, but the fact that the study was self-funded and had no financial help from external sources limited our possibility only to the rural population attending a private dental college.

Comparison of periodontal parameters in our study revealed that patients in the SD and ND groups had higher mean percentage of BOP compared to the NH and SH groups. Our findings attain support from a study by Ramseier *et al*.[@ref23] who reported that mean BOP significantly increased with periodontal disease severity, irrespective of the smoking status. However, there was an absence of BOP in healthy smoker group.

This could be explained by the fact that smoking leads to decrease in vascular density and reduced lumen area of gingival vessels and causes vasoconstriction in peripheral blood vessels and also an increase in the thickness of gingival epithelium.[@ref24][@ref25][@ref26]

A significant finding in our study was that diseased sites in nonsmokers and smokers had significantly elevated IL-1β profiles as compared with healthy sites. This relative increase in IL-1β in diseased smokers is consistent with a previous research by Kamma *et al*.[@ref14] and Zhong *et al*.[@ref27] who reported greater total amounts of IL-1β in smokers. This can be explained by the fact that nicotine, an active content of smoke, impairs the gingival blood flow with its vasoconstrictive properties and creates an anaerobic environment conducive for the growth of periodontal bacteria.[@ref28][@ref29] An increase in these anaerobes enhances greater stimulation of the gingival monocytes and macrophages, resulting in an increased production of IL-1β.[@ref29] Further, the oral keratinocytes are quite sensitive to cigarette smoke and react with an increased production of inflammatory mediators such as PGE~2~ and IL-1, contributing to periodontal destruction.[@ref30]

In contrast, Rawlinson *et al*.[@ref13] reported lower GCF levels of IL-1β among smokers. The differences in IL-1β levels among smokers could be attributed to a number of factors such as nature of the host response, variables associated with smoking, techniques employed in the collection of GCF, and lab technicalities in the analysis of a GCF assay.[@ref16]

There was also a reported increase in IL-1β in diseased nonsmokers compared to the healthy controls. This finding corroborates with other studies which reported increased GCF amounts of pro-inflammatory cytokines, especially IL-1β in periodontitis patients.[@ref31][@ref32]

The present study also analyzed GCF levels of IL-8. Our results exhibit a reduction of IL-8 among smokers. The findings in our study corroborate with those of Tymkiv *et al*.[@ref16] who reported similar reductions of IL-8 in GCF of smokers. Our study did not find any significant difference in the chemokine levels of smokers with periodontitis when compared with the healthy smokers. However, a significant difference in chemokine levels has been found when nonsmokers with periodontitis were compared with smokers, both healthy and those with periodontitis. This reduction in IL-8 levels in smokers leads to impaired neutrophil chemotaxis and migration in the periodontium, paving way for the progression of periodontal disease.[@ref33] Our results are at variance with those of Lütfioǧlu *et al*.[@ref34] who reported increases in GCF IL-8 levels in smokers.

Our study revealed that the periodontal parameters such as PD, REC, and CAL were higher and statistically significant in the SD and SH groups when compared with the ND and NH groups. Our findings agree with the studies by Rosa *et al*.[@ref35] and Calsina *et al*.[@ref36] who also reported a direct relation between an increased consumption of smoking and periodontal destruction. Literature is replete with evidence that supports that smokers are at a higher risk of having periodontitis with higher attachment loss as compared with nonsmokers.[@ref37][@ref38]

Our study shows a correlation between clinical parameters and cytokine levels in the study groups. There was a positive association in the SD and ND groups reflected by an increased PD and CAL associated with elevated IL-1β levels. Our findings were similar to those of Engebretson *et al*.[@ref39] who reported a statistically significant correlation between IL-1β GCF levels and clinical parameters with severe disease sites, showing a higher IL-1β GCF level when compared to the shallow sites.

C[ONCLUSIONS]{.smallcaps} {#sec1-5}
=========================

Within the limitations of the present study, it can be concluded that smoking appears to have an inhibitory effect on chemokine production reflected by a reduced amount of IL-8 levels in GCF. Hence, smoking induces an immunosuppressed state reducing the individual\'s capacity to fight periodontal diseases. Smokers with periodontitis exhibited higher levels of IL-1β compared with nonsmokers, which could explain the increased periodontal destruction in smokers.

However, a small sample size restrains us in giving a robust conclusion. A larger sample employing novel assay methods would help us in correlating the influence of smoking on the cytokine profile and periodontal destruction.
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